Compare Medtronic PLC (MDT) vs Nebius Group NV (NBIS) Price & Performance

Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.

MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.

NBIS trades at $237.07, down 5.08% today, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company shows strong revenue growth with 2026 projections reaching $1.4B, though profitability remains challenged with a net margin of 3.13%. Recent acquisitions like Inferize and partnerships with Nvidia and Palantir position NBIS as a key player in AI infrastructure, supported by an 81.82% analyst buy rating and $272.70 consensus price target.

Outlook: NBIS benefits from AI demand and a $37B backlog but faces execution risks from heavy spending ($11.4B investing outflow in 2026) and high valuations (P/E 845). Insider selling and competitive pressures from hyperscalers pose near-term headwinds, though institutional bullishness suggests long-term growth potential if operational targets are met.